- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04092556
tDCS for Multiple System Atrophy With Cerebellar Feature
Exploratory Study to Evaluate the Effective Site for Control of Motor Coordination Function After Transcranial Direct Current Stimulation in Multiple Systemic Atrophy With Cerebellar Feature
Study Overview
Status
Intervention / Treatment
Detailed Description
Participants receive transcranial direct current stimulation (tDCS) over M1, cerebellar cortex or sham stimulation for 30 minutes. The type of stimulation depends on random assignment. The participants have a 1 week of wash out period between each stimulation.
The assessment will be done by International Cooperative Ataxia Rating Scale (ICARS), GAITRITE (CIR Systems Inc., Clifton, New Jersey, USA) and PEDOSCAN (DIERS PEDO, Germany) at baseline and immediately after each treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jinyoung Youn
- Phone Number: 82-2-3410-0245
- Email: genian@skku.edu
Study Contact Backup
- Name: Jong Hyeon Ahn
- Phone Number: 82-2-3410-0245
- Email: jonghyeon.ahn@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Jinyoung Youn
- Phone Number: 82-2-3410-0245
- Email: genian@skku.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Patients who meet the clinical criteria for probable multiple system atrophy with cerebellar features (MDS second consensus statement on the diagnosis of multiple system atrophy)
- 2. Patients aged between 40 and 70
- 3. Patients who do not have rigidity and bradykinesia
- 4. Patients who have given voluntary consent after understanding the content of the clinical trial
Exclusion Criteria:
- 1. Patients with a serious cognitive disorder, behavioral disorder, or mental illness
- 2. Patients have history of seizure, stroke, encephalitis, other degenerative neurological disease
3. Patients with a serious medical disease
- Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease
- Patients with un-controlled high blood pressure or diabetes
- 4. Patients who have taken another investigational products within 4 weeks prior to being enrolled in this clinical trial, or patients who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: tDCS (M1)
The participants will be submit to tDCS applied over the motor cortex (M1)
|
tDCS involves application of very low amplitude direct current via surface scalp electrodes.
The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability.
Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
Other Names:
|
Active Comparator: tDCS (Cerebellar cortex)
The participants will be submit to tDCS applied over the cerebellar cortex
|
tDCS involves application of very low amplitude direct current via surface scalp electrodes.
The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability.
Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
Other Names:
|
Sham Comparator: Sham stimulation
The participants will be submit to sham stimulation
|
tDCS involves application of very low amplitude direct current via surface scalp electrodes.
The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability.
Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from International Cooperative Ataxia Rating Scale (ICARS)
Time Frame: per session: at baseline and within 30 minutes tDCS treatment completion
|
The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders.
Higher scores indicate higher levels of impairment.
|
per session: at baseline and within 30 minutes tDCS treatment completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from temporospatial parameters of gait
Time Frame: per session: at baseline and within 30 minutes tDCS treatment completion
|
Gait parameters measured by GAITRite system
|
per session: at baseline and within 30 minutes tDCS treatment completion
|
Change from posturography
Time Frame: per session: at baseline and within 30 minutes tDCS treatment completion
|
Posturography measured by Pedoscan system
|
per session: at baseline and within 30 minutes tDCS treatment completion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jinyoung Youn, Samsung Medical Center, Department of Neurology
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Pathological Conditions, Anatomical
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Hypotension
- Atrophy
- Multiple System Atrophy
- Shy-Drager Syndrome
Other Study ID Numbers
- 2018-10-010-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple System Atrophy, Cerebellar Variant (Disorder)
-
Brigham and Women's HospitalBiohaven Pharmaceuticals, Inc.CompletedMultiple System Atrophy | Multiple System Atrophy, Parkinson Variant (Disorder) | Multiple System Atrophy, Cerebellar Variant | Multiple System Atrophy (MSA) With Orthostatic HypotensionUnited States
-
Samsung Medical CenterCompletedSpinocerebellar Ataxias | Multiple System Atrophy, Cerebellar Variant (Disorder)Korea, Republic of
-
zhangyuqingRecruitingMultiple System Atrophy, Parkinson Variant (Disorder)China
-
National Taiwan University HospitalTerminatedMultiple System Atrophy | Ataxia, CerebellarTaiwan
-
Indonesia UniversityRecruitingParkinsonism | Multiple System Atrophy | Multiple System Atrophy, Parkinson VariantIndonesia
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMultiple System Atrophy - Parkinsonian Subtype (MSA-P) | Multiple System Atrophy - Cerebellar Subtype (MSA-C)United States
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingSpinocerebellar Ataxia Type 3 | Multiple System Atrophy-cerebellar TypeChina
-
Asklepios Biopharmaceutical, Inc.RecruitingParkinson's Disease | Multiple System Atrophy | Multiple System Atrophy, Parkinson VariantUnited States, Poland
-
Universitätsklinik für Neurologie, InnsbruckMedical University Innsbruck; University of Erlangen-Nürnberg, Germany; University... and other collaboratorsRecruitingParkinson Disease | Progressive Supranuclear Palsy | Multiple System Atrophy, Parkinson Variant (Disorder)Austria
-
Chang Gung UniversityCompleted
Clinical Trials on transcranial direct current stimulation
-
Federal University of ParaíbaCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
University of Campinas, BrazilUnknownEpilepsy IntractableBrazil
-
Dina Hatem ElhammadyUnknown
-
Shirley Ryan AbilityLabNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Nonfluent AphasiaUnited States
-
University of Texas Rio Grande ValleyRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Federal University of ParaíbaUnknown
-
University of CalgaryAlberta Health servicesRecruitingCervicogenic HeadacheCanada
-
Universidade Federal do Rio Grande do NorteNot yet recruitingLow Back Pain | Transcranial Direct Current Stimulation
-
Nanyang Technological UniversityActive, not recruiting